The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a more substantial decrease in